Twist Bioscience Corporation (TWST) Misses Q4 EPS by 11c
Get Alerts TWST Hot Sheet
Join SI Premium – FREE
Twist Bioscience Corporation (NASDAQ: TWST) reported Q4 EPS of ($0.96), $0.11 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $15.7 million versus the consensus estimate of $14.06 million.
GUIDANCE:
Twist Bioscience Corporation sees FY2020 revenue of $80-84 million, versus the consensus of $80.15 million.
- Revenue from Ginkgo Bioworks expected to be approximately $10 million
- Synbio revenue excluding Ginkgo Bioworks is expected to be in the range of $32 to $33 million
- NGS revenue is estimated to be in the range of $37 to $40 million
- Biopharma revenue is estimated to be approximately $1 million
Twist Bioscience Corporation sees Q1 2020 revenue of $15-16.5 million, versus the consensus of $15.92 million.
- Net loss expected in the range of $31 million to $32 million
For earnings history and earnings-related data on Twist Bioscience Corporation (TWST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Mohawk Industries (MHK) Tops Q1 EPS by 19c
- ResMed (RMD) Tops Q3 EPS by 20c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!